ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (224 K)

Article Toolbox
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.pharmthera.2005.01.004    
How to Cite or Link Using DOI (Opens New Window)

Copyright © 2005 Published by Elsevier Inc.

Associate editor: J. Wess

The clinical potential of chemokine receptor antagonists

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Sofia Ribeiro and Richard HorukCorresponding Author Contact Information, E-mail The Corresponding Author

Department of Molecular Pharmacology, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, USA

Department of Immunology, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, USA


Available online 13 May 2005.

Abstract

Chemokines belong to a family of chemotactic cytokines that direct the migration of immune cells towards sites of inflammation. They mediate their biological effects by binding to cell surface receptors, which belong to the G protein-coupled receptor superfamily. Since chemokines and their receptors have been implicated in the pathophysiology of a number of autoinflammatory diseases, chemokine receptor antagonists could prove to be useful therapeutics to target these diseases. Here, we review the role of chemokines in autoimmunity, concentrating mainly on the chemokine receptors CCR1 and CCR5, and discuss the potential utility of antagonists that target these 2 receptors as they progress through the clinic.

Keywords: Chemokine; G-protein coupled receptor; Receptor antagonists; Autoimmune disease; Multiple sclerosis; Clinical trials

Article Outline

1. Introduction
2. Chemokines and their receptors
3. Chemokines in multiple sclerosis
4. Chemokines in rheumatoid arthritis
5. Chemokines in diabetes
6. Chemokines in endometriosis
7. Chemokines in organ transplant rejection
8. Chemokines in multiple myeloma
9. CCR1 antagonists
10. CCR5 antagonists
11. Conclusion
12. Note added in proof
References





Corresponding Author Contact InformationCorresponding author. Department of Immunology, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94804, USA. Tel.: 510 669 4625; fax: 510 669 4244.

 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.